Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cimzia certolizumab pegol: Additional Phase III data

Additional data from the double-blind, international Phase III RAPID 1 trial showed that at 12 months, both doses of Cimzia

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE